Korys invests in genae
This transaction underlines the commitment of genae’s management to accelerate the group’s development, now backed by a strong and culturally compatible equity partner.
“With this investment, Korys takes part in a medical device CRO that is capable of providing high-quality research services on a global scale, assisting their partners in bringing new therapies and products to market. We look at genae and its innovative and entrepreneurial team as strong contributors to our 3P (people-planet-profit) vision” said Vincent Vliebergh, Korys’ CEO.
“The entrance of Korys accelerates genae’s strategy to further strengthen our position as the leading medical device CRO in Europe, while continuing to build critical scale in the US and Japan,” said Bart Segers, genae’s CEO.
About the genae group
genae is involved in the development and commercialization of medical devices, biologics and therapies that change medical practice. genae is a full service CRO and services provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. The group’s Quality Management System has been tested rigorously and continues to pass regulatory and sponsor’s audits and inspections. genae associates nv is a privately held company with principal offices in Antwerp, Belgium and is part of the genae group, the medical device CRO.
To learn more about genae, please visit http://www.genae.com.